In addition, the prediction model constructed based on features of peripheral immune cells in the present study is promising to screen beneficiaries of EGFR-TKI-resistant NSCLC patients from ICI plus chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.